In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in blood ...

Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

Researchers identify a shared RNA-protein interaction that could lead to broad-spectrum antiviral treatments for enteroviruses ...

Novartis has agreed to license and develop Arrowhead Pharmaceuticals’ preclinical stage small interfering RNA (siRNA) therapy ARO-SNCA, a potential treatment for Parkinson’s disease and other ...

Viruses occupy a central place in ecology and health, influencing the dynamics of terrestrial, aquatic, and managed ...

With the question of immunotherapeutics’ efficacy answered in the resounding affirmative, the challenge has shifted to the practical considerations of how to cost-effectively manufacture these highly ...

With the support of two new funding sources — including a gift from a Brown trustee and a grant from the National Institutes of Health — Brown is expanding RNA research on campus in a continued effort ...